EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 3.0

Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies

Sung Wook Cho, Sung Hee Lim, Ghee Young Kwon, Chan Kyo Kim, Won Park, Hongryull Pyo, Jae Hoon Chung, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2024.015 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Sung Wook Cho und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cisplatin, Neoadjuvant Therapy, Chemoradiotherapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: HSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies was performed to better evaluate the feasibility of selective bladder preservation CRT.Materials and Methods The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT.

Results

Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine and cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n=20), metastatic only (n=16), and both (n=7). In 27 patients with intravesical recurrence, transurethral resection, and Bacillus Calmette-Guerin treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% confidence interval [CI], 25.1 to 67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (hazard ratio, 0.465; 95% CI, 0.222 to 0.976).

Conclusion

The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCisplatinNeoadjuvant TherapyChemoradiotherapyHumansMaleFemaleAgedMiddle AgedProspective StudiesAntineoplastic Combined Chemotherapy ProtocolsOrgan Sparing TreatmentsTreatment OutcomeNeoplasm InvasivenessAdultCarcinoma, Transitional CellDeoxycytidineAged, 80 and overGemcitabine

Stichwörter der Autor:innen

Muscle-invasiveNeoadjuvant chemoradiotherapyUrinary bladder neoplasms

Substanzen

CisplatinDeoxycytidineGemcitabine

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Förderung

  • HSRD VA

Zitieren

APA

Cho, S. W., Lim, S. H., Kwon, G. Y., Kim, C. K., Park, W., Pyo, H., Chung, J. H., Song, W., Sung, H. H., Jeong, B. C., & Park, S. H. (2024). Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.015

Vancouver

Cho SW, Lim SH, Kwon GY, Kim CK, Park W, Pyo H, et al. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.015

BibTeX
@article{Cho2024,
  author = {Cho, Sung Wook and Lim, Sung Hee and Kwon, Ghee Young and Kim, Chan Kyo and Park, Won and Pyo, Hongryull and Chung, Jae Hoon and Song, Wan and Sung, Hyun Hwan and Jeong, Byong Chang and Park, Se Hoon},
  title = {Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2024.015}
}
Kostenlos starten →